340 related articles for article (PubMed ID: 22995952)
1. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution.
Turaka K; Bryan JS; De Souza S; Gordon AJ; Kwong HM; Ziemianski MC; Reddy R; Sell CH
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):412-7. PubMed ID: 22995952
[TBL] [Abstract][Full Text] [Related]
2. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
[TBL] [Abstract][Full Text] [Related]
3. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.
Akpek EK; Ahmed I; Hochberg FH; Soheilian M; Dryja TP; Jakobiec FA; Foster CS
Ophthalmology; 1999 Sep; 106(9):1805-10. PubMed ID: 10485554
[TBL] [Abstract][Full Text] [Related]
4. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes.
Levasseur SD; Wittenberg LA; White VA
JAMA Ophthalmol; 2013 Jan; 131(1):50-5. PubMed ID: 23307208
[TBL] [Abstract][Full Text] [Related]
5. Role of systemic high-dose methotrexate and combined approaches in the management of vitreoretinal lymphoma: A single center experience 1990-2018.
Castellino A; Pulido JS; Johnston PB; Ristow KM; Nora Bennani N; Inwards DJ; Macon WR; Micallef INM; King RL; Salomao DR; Witzig TE; Habermann TM; Nowakowski GS
Am J Hematol; 2019 Mar; 94(3):291-298. PubMed ID: 30516868
[TBL] [Abstract][Full Text] [Related]
6. Use of intravitreal rituximab for treatment of vitreoretinal lymphoma.
Larkin KL; Saboo US; Comer GM; Forooghian F; Mackensen F; Merrill P; Sen HN; Singh A; Essex RW; Lake S; Lim LL; Vasconcelos-Santos DV; Foster CS; Wilson DJ; Smith JR
Br J Ophthalmol; 2014 Jan; 98(1):99-103. PubMed ID: 24158837
[TBL] [Abstract][Full Text] [Related]
7. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
8. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.
Zhou X; Zhou X; Shi H; Lai J; Wang Q; Li Y; Chen K; Li Q; Zhou Q; Cao X; Chen B; Xiao J
BMC Ophthalmol; 2020 May; 20(1):189. PubMed ID: 32397978
[TBL] [Abstract][Full Text] [Related]
9. Tumor Control and Visual Acuity Outcomes in Vitreoretinal Lymphoma with and without Sub-Retinal Pigment Epithelium Infiltration: Analysis of 125 Eyes of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Mashayekhi A; Shields CL
Ophthalmol Retina; 2019 Nov; 3(11):998-1005. PubMed ID: 31358444
[TBL] [Abstract][Full Text] [Related]
10. Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India.
Rishi P; Manchegowda PT; Gondhale HP; Rishi E; Das K; Krishnakumar S; Raja T; Biswas J
Int Ophthalmol; 2021 Jul; 41(7):2495-2504. PubMed ID: 33730314
[TBL] [Abstract][Full Text] [Related]
11. Curious case of bilateral non-resolving vitritis - Unmasking the masquerade on ultra-widefield imaging.
Delhiwala K
Indian J Ophthalmol; 2022 Apr; 70(4):1438-1439. PubMed ID: 35326082
[TBL] [Abstract][Full Text] [Related]
12. More than a masquerade syndrome: atypical presentations of vitreoretinal lymphomas.
AlQahtani A; Touitou V; Cassoux N; Aknin C; Merle-Beral H; Bodaghi B; LeHoang P
Ocul Immunol Inflamm; 2014 Jun; 22(3):189-96. PubMed ID: 24475870
[TBL] [Abstract][Full Text] [Related]
13. Multimodal imaging characteristics in eyes with vitreoretinal lymphoma treated with intravitreal rituximab.
Rishi P; Maitra P; Das K; Rishi E; Manchegowda PT
Int Ophthalmol; 2021 Aug; 41(8):2711-2722. PubMed ID: 33834345
[TBL] [Abstract][Full Text] [Related]
14. Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A Potential Less Invasive Method for Diagnosis and Treatment Response Assessment.
Demirci H; Rao RC; Elner VM; Demirci FY; Axenov L; Betz B; Behdad A; Brown N
Ophthalmol Retina; 2023 Feb; 7(2):189-195. PubMed ID: 35952929
[TBL] [Abstract][Full Text] [Related]
15. Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center.
Giuffrè C; Cicinelli MV; Marchese A; Modorati GM; Brambati M; Ferreri AJM; Calimeri T; Ponzoni M; Bandello F; Miserocchi E
Ocul Immunol Inflamm; 2021 Apr; 29(3):472-478. PubMed ID: 32845738
[No Abstract] [Full Text] [Related]
16. Clinical Features and Treatment Outcomes of Vitreoretinal Lymphoma according to Its Association with CNS Lymphoma.
Cho BJ; Kim DY; Park UC; Lee JY; Yoon YH; Yu HG
Ocul Immunol Inflamm; 2018; 26(3):365-371. PubMed ID: 29394118
[TBL] [Abstract][Full Text] [Related]
17. Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome.
Chaput F; Amer R; Baglivo E; Touitou V; Kozyreff A; Bron D; Bodaghi B; LeHoang P; Bergstrom C; Grossniklaus HE; Chan CC; Pe'er J; Caspers LE
Ocul Immunol Inflamm; 2017 Oct; 25(5):639-648. PubMed ID: 27002464
[TBL] [Abstract][Full Text] [Related]
18. INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA: Case Series.
Guneri Beser B; Demirci H
Retina; 2024 Feb; 44(2):353-359. PubMed ID: 37883576
[TBL] [Abstract][Full Text] [Related]
19. [Intraocular lymphoma--a clinical study of 14 patients with non-Hodgkin's lymphoma].
Ríhová E; Sisková A; Jandusová J; Kovarík Z; Sach J; Adam P
Cesk Slov Oftalmol; 2004 Jan; 60(1):3-16. PubMed ID: 15011301
[TBL] [Abstract][Full Text] [Related]
20. Clinical review: treatment of vitreoretinal lymphoma.
Pe'er J; Hochberg FH; Foster CS
Ocul Immunol Inflamm; 2009; 17(5):299-306. PubMed ID: 19831557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]